Mokast (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding. This inhibition stops the cascade that leads to bronchoconstriction, mucus production, and inflammation, resulting in better airway patency and reduced allergic symptoms.

The appropriate dose of Mokast is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Dosage regimens may differ for asthma, allergic rhinitis, or exercise‑induced bronchoconstriction, and should follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order Mokast, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mokast belongs to the leukotriene receptor antagonist class, which differs from inhaled corticosteroids and bronchodilators. It is taken orally once daily and is particularly useful for patients who need additional control beyond inhaled therapy or who experience exercise‑related bronchoconstriction. Choice of therapy depends on individual disease patterns and physician assessment.

Mokast tablets should be stored at ambient temperature below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mokast is administered orally, usually as a single tablet taken with or without food once daily, as directed by the prescriber. Swallow the tablet whole with water; do not crush or chew unless specifically instructed.

Serious adverse events linked to Montelukast include allergic reactions such as rash, urticaria or angioedema, neuropsychiatric effects like mood changes or rare suicidal thoughts, and liver function abnormalities. Patients should seek immediate medical attention if they notice any of these symptoms.

Mokast should be avoided in individuals with known hypersensitivity to Montelukast or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and it is not recommended for use in children under the age approved for the specific indication without medical guidance.